卡巴拉汀治疗皮质下血管性痴呆：一项针对208例患者的随机、对照、为期12个月的开放性研究。
Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients.
作者信息
Moretti Rita, Torre Paola, Antonello Rodolfo M, Cazzato Giuseppe, Bava Antonio
机构信息
Dipartimento di Fisiologia e Patologia, Dipartimento di Medicina Clinica e Neurologia, Ambulatorio Disturbi Cognitivi, Università degli Studi di Trieste, Trieste, Italy.
出版信息
Am J Alzheimers Dis Other Demen. 2003 Sep-Oct;18(5):265-72. doi: 10.1177/153331750301800508.
Abstract
Subcortical vascular dementia (VaD) is characterized by executive dysfunction and behavioral problems, reflecting deterioration of the frontal lobe. This study aimed to determine whether rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyryl-cholinesterase (BuChE), has any effects on the typical symptoms of subcortical VaD. Patients receiving rivastigmine showed a slight improvement in executive functions and in behavior. Side effects in both groups were tolerable and there were no study withdrawals. Moreover, there are no drug interactions with other therapies previously and concomitantly assumed. Improvements in domains that characterize subcortical VaD were observed, indicating that rivastigmine may have provided targeted treatment in areas of the brain that are particularly affected in this patient population.
摘要
皮质下血管性痴呆（VaD）的特征是执行功能障碍和行为问题，反映出额叶的退化。本研究旨在确定乙酰胆碱酯酶（AChE）和丁酰胆碱酯酶（BuChE）的双重抑制剂卡巴拉汀是否对皮质下VaD的典型症状有任何影响。接受卡巴拉汀治疗的患者在执行功能和行为方面有轻微改善。两组的副作用均可耐受，且无患者退出研究。此外，之前和同时假设的与其他疗法均无药物相互作用。观察到了皮质下VaD特征性领域的改善，表明卡巴拉汀可能为该患者群体中受影响特别严重的脑区提供了针对性治疗。
相似文献
1
Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients.卡巴拉汀治疗皮质下血管性痴呆：一项针对208例患者的随机、对照、为期12个月的开放性研究。
Am J Alzheimers Dis Other Demen. 2003 Sep-Oct;18(5):265-72. doi: 10.1177/153331750301800508.
2
Rivastigmine in vascular dementia.卡巴拉汀治疗血管性痴呆
Expert Opin Pharmacother. 2004 Jun;5(6):1399-410. doi: 10.1517/14656566.5.6.1399.
3
Rivastigmine in subcortical vascular dementia: an open 22-month study.卡巴拉汀治疗皮质下血管性痴呆：一项为期22个月的开放性研究。
J Neurol Sci. 2002 Nov 15;203-204:141-6. doi: 10.1016/s0022-510x(02)00280-0.
4
Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study.在皮质下血管性痴呆中，卡巴拉汀优于阿司匹林加尼莫地平：一项为期16个月的开放性对照研究。
Int J Clin Pract. 2004 Apr;58(4):346-53. doi: 10.1111/j.1368-5031.2004.00127.x.
5
Rivastigmine in vascular dementia.卡巴拉汀治疗血管性痴呆
Int Psychogeriatr. 2003;15 Suppl 1:201-5. doi: 10.1017/S1041610203009207.
6
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.卡巴拉汀：乙酰胆碱酯酶和丁酰胆碱酯酶双重抑制的优势及其在皮质下血管性痴呆和帕金森病痴呆中的作用。
Clin Interv Aging. 2017 Apr 18;12:697-707. doi: 10.2147/CIA.S129145. eCollection 2017.
7
8
Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.卡巴拉汀对阿尔茨海默病患者脑脊液中乙酰胆碱酯酶和丁酰胆碱酯酶的抑制作用：与认知改善的相关性
J Neural Transm (Vienna). 2002 Jul;109(7-8):1053-65. doi: 10.1007/s007020200089.
9
Rivastigmine for subcortical vascular dementia.卡巴拉汀用于治疗皮质下血管性痴呆。
Expert Rev Neurother. 2005 May;5(3):309-13. doi: 10.1586/14737175.5.3.309.
10
The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.胆碱酯酶抑制剂对阿尔茨海默病和血管性痴呆患者局部血流的影响。
J Neurol Sci. 2003 Dec 15;216(1):119-26. doi: 10.1016/s0022-510x(03)00229-6.
引用本文的文献
1
Unraveling the role of brain renin angiotensin system in vascular dementia: mechanisms and therapeutic perspectives.解析脑肾素血管紧张素系统在血管性痴呆中的作用：机制与治疗前景
Exp Brain Res. 2025 Apr 26;243(5):130. doi: 10.1007/s00221-025-07072-1.
2
Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine.痴呆症临床实践指南：胆碱酯酶抑制剂和美金刚的推荐意见
Dement Neurocogn Disord. 2025 Jan;24(1):1-23. doi: 10.12779/dnd.2025.24.1.1. Epub 2025 Jan 20.
3
Vascular cognitive impairment and dementia: a narrative review.血管性认知障碍与痴呆：一篇叙述性综述。
Dement Neuropsychol. 2024 Sep 23;18:e20230116. doi: 10.1590/1980-5764-DN-2023-0116. eCollection 2024.
4
Pharmacological treatments for vascular dementia: a systematic review and Bayesian network meta-analysis.血管性痴呆的药物治疗：系统评价与贝叶斯网络荟萃分析
Front Pharmacol. 2024 Aug 22;15:1451032. doi: 10.3389/fphar.2024.1451032. eCollection 2024.
5
Vascular Cognitive Impairment (VCI).血管性认知障碍（VCI）。
Neurotherapeutics. 2022 Jan;19(1):68-88. doi: 10.1007/s13311-021-01170-y. Epub 2021 Dec 22.
6
Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias.在非阿尔茨海默病痴呆中使用胆碱酯酶抑制剂。
Drugs Aging. 2019 Aug;36(8):719-731. doi: 10.1007/s40266-019-00685-6.
7
Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis.治疗血管性认知障碍的认知增强剂的疗效和安全性比较：系统评价与贝叶斯网络Meta分析
Neural Regen Res. 2019 May;14(5):805-816. doi: 10.4103/1673-5374.249228.
8
Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis.他汀类药物治疗对痴呆风险、认知变化及其病理改变的影响概述：一项系统评价和荟萃分析
Ann Transl Med. 2018 Nov;6(22):435. doi: 10.21037/atm.2018.06.43.
9
Treatment of vascular dementia. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology.血管性痴呆的治疗。巴西神经病学学会认知神经病学与衰老科学部的建议。
Dement Neuropsychol. 2011 Oct-Dec;5(4):275-287. doi: 10.1590/S1980-57642011DN05040005.
10
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.卡巴拉汀：乙酰胆碱酯酶和丁酰胆碱酯酶双重抑制的优势及其在皮质下血管性痴呆和帕金森病痴呆中的作用。
Clin Interv Aging. 2017 Apr 18;12:697-707. doi: 10.2147/CIA.S129145. eCollection 2017.
本文引用的文献
1
Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study.在皮质下血管性痴呆中，卡巴拉汀优于阿司匹林加尼莫地平：一项为期16个月的开放性对照研究。
Int J Clin Pract. 2004 Apr;58(4):346-53. doi: 10.1111/j.1368-5031.2004.00127.x.
2
Rivastigmine in subcortical vascular dementia: an open 22-month study.卡巴拉汀治疗皮质下血管性痴呆：一项为期22个月的开放性研究。
J Neurol Sci. 2002 Nov 15;203-204:141-6. doi: 10.1016/s0022-510x(02)00280-0.
3
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.加兰他敏治疗可能的血管性痴呆及阿尔茨海默病合并脑血管病的疗效：一项随机试验。
Lancet. 2002 Apr 13;359(9314):1283-90. doi: 10.1016/S0140-6736(02)08267-3.
4
Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease.阿尔茨海默病中脑血流量及对 rivastigmine 治疗的认知反应
Neuroreport. 2002 Jan 21;13(1):83-7. doi: 10.1097/00001756-200201210-00020.
5
Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe.路易体痴呆中的视幻觉与颞叶中的路易体有关。
Brain. 2002 Feb;125(Pt 2):391-403. doi: 10.1093/brain/awf033.
6
Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.阿尔茨海默病治疗进展：双重胆碱酯酶抑制的益处
Eur Neurol. 2002;47(1):64-70. doi: 10.1159/000047952.
7
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.卡巴拉汀治疗帕金森病性精神病和认知障碍：一项开放性试验的初步结果
Mov Disord. 2001 Nov;16(6):1171-4. doi: 10.1002/mds.1204.
8
Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up.卡巴拉汀治疗皮质下血管性痴呆：一项为期12个月随访的疗效和耐受性比较试验。
Eur J Neurol. 2001 Jul;8(4):361-2. doi: 10.1046/j.1468-1331.2001.00224.x.
9
Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients.短期服用卡巴拉汀可降低阿尔茨海默病患者脑电图的慢波功率。
Neuropsychobiology. 2001;43(4):273-6. doi: 10.1159/000054902.
10
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.卡巴拉汀治疗路易体痴呆的疗效：一项随机、双盲、安慰剂对照的国际研究。
Lancet. 2000 Dec 16;356(9247):2031-6. doi: 10.1016/S0140-6736(00)03399-7.
Zotero 插件